louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05534334: Corticosteroid Intralesional Injection as an Alternative Treatment in Oral Pyogenic Granuloma in the Esthetic Zone.
Official title: Corticosteroid Intralesional Injection as an Alternative Treatment in Oral Pyogenic Granuloma in the Esthetic Zone
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Oral Pyogenic Granuloma
Lead sponsor: Beni-Suef University
Sponsor class: OTHER
First posted: 2022-09-09
Enrollment: 30
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Gingival Pyogenic granuloma in the esthetic zone represents an esthetic problem. While surgical treatment may not give the premium esthetic demands, corticosteroid may acheive this balance.

Detailed description: In our practice, the investigators have found the use of topical steroids effectively induced regression of PGs. This protocol has been suggested by published case reports supported by the anti-inflammatory actions corticosteroid.

This is a particularly valuable approach for patients who have PG in the esthetic zone allowing the surgeon to keep maximum amount of periodontal tissues.

Eligibility criteria: Inclusion Criteria:

* Patients with oral pyogenic granuloma at the esthetic zone

Exclusion Criteria:

* Patients who were not compliant to oral hygiene instructions and can not be motivated

Primary outcomes:
measure: Remaining width of the attached gingiva
timeFrame: 6 month
Secondary outcomes:
measure: Recurrence of the lesion
timeFrame: 6 months
Other outcomes:
Locations:
city: Banī Suwayf
country: Egypt
facility: Beni_Suef University
state: Bani Suwayf
city: Banī Suwayf
country: Egypt
facility: Eman Ahmed
state: Benisuef
Study officials:
affiliation: Lecturer
name: Eman Magdy, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02418234: T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure
Official title: Frequency and Abundance of T790M Mutation on Circulating Tumor DNA in Patients With Non-small Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment Failure: a Perspective Observational Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Non-small Cell Lung Cancer Stage III
Non-Small-Cell Lung Cancer Metastatic
Keywords: Non-small Cell Lung Cancer
circulating tumor DNA
T790M
amplification refractory mutation system
digital droplet PCR
Lead sponsor: First People's Hospital of Hangzhou
Sponsor class: OTHER
First posted: 2015-04-16
Enrollment: 314
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with Non small cell lung cancer (NSCLC) after EGFR-TKI failure

Brief summary: The purpose of this study is to compare the frequency and abundance of T790M mutation among the different Clinical modes of EGFR-TKI failure.

Detailed description: An observational, non-interventional, multi-central study of comparison of the frequency and abundance of T790M mutation using both amplification refractory mutation system (ARMS) and digital droplet PCR (ddPCR) methods among the different Clinical modes of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) failure

Eligibility criteria: Inclusion Criteria:

* Histologically confirmed stage IIIB/IV NSCLC.
* Investigator confirmed progression according RECIST 1.1 during EGFR-TKI treatment within 28 days of the enrollment
* Activating mutation (G719A/C/S; Exon 19 insertion/deletion; L858R; L861Q) in the EGFR gene or have had at least partial response with EGFR TKI lasting ≥ 6 months
* Patient must be able to comply with the protocol

Exclusion Criteria:

* Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 defined disease progression for more than 28 days while on previous EGFR-TKI treatment.
* Patient has been treated with any investigational agent for any indication within 4 weeks of study treatment.
* Histologically confirmed small cell lung cancer or other metastatic tumors
* Patient with no histologic or cytological diagnosis.

Primary outcomes:
measure: Number of Patients With T790M Mutation Detected by Amplification Refractory Mutation System (ARMS) Assay
timeFrame: up to 2 years
measure: Abundance of T790M Mutation Detected by Digital Droplet PCR (ddPCR) Assay in Each Individual Patient
timeFrame: up to 2 years
Secondary outcomes:
measure: Number of T790M Mutation by ARMS and ddPCR Assays in Each Different Clinical Modes of TKI Failure
timeFrame: up to 2 years
measure: Differences of T790M Mutation by ddPCR Among the Different Clinical Modes of TKI Failure
timeFrame: up to 2 years
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Hangzhou First People's Hospital
state: Zhejiang
Study officials:
References:
Clinical trial NCT03437434: Scleral Fixation of BunnyLens With GoreTex Suture- Initial Results
Official title: Gore-Tex Suture and BunnyLens Scleral Fixation - Historical Retrospective Trial
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Aphakia, Acquired
Lead sponsor: Barzilai Medical Center
Sponsor class: OTHER
First posted: 2018-02-19
Enrollment: 40
Sex: ALL
Minimum age (years): 15
Maximum age (years): 99
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who are capable of inform consent and are eligible according to the inclusion criteria.

Brief summary: This study evaluates the Visual Acuity and refraction of patients post 4-point Scleral fixation of BunnyLens (Intra Ocular Lens- IOL) with GoreTex sutures. All patients underwent secondary IOL implantation or IOL exchange during 2014-2017.

Detailed description: 4 point scleral fixation of PC- IOL (Posterior Chamber-PC) BunnyLens with Gore-Tex sutures is a surgical technique for implanting IOL in patients with capsular support absence, due to trauma, abnormal anterior chamber, IOL dislocation, or ciliary zonule defect.

The 4 point fixation enables to align the PC- IOL with minimal vertical and horizontal deviation;The Gore-Tex sutures maintain stable scleral fixation with no suture erosion or breakage.

Eligibility criteria: Inclusion Criteria:

* patients that underwent secondary cataract surgery or IOL replacement and BunnyLens fixation with Gore-Tex sutures.

Exclusion Criteria:

* Lack of Cooperation, death, severe physical or mental illness, patient's request to withdraw of the clinical trial.

Primary outcomes:
measure: Distance Visual Acuity
timeFrame: Up to 24 months from surgery.
measure: Ocular Refraction
timeFrame: Up to 24 months from surgery.
Secondary outcomes:
measure: Slit Lamp Biomicroscopy
timeFrame: Up to 24 months from surgery.
Other outcomes:
Locations:
city: Ashkelon
country: Israel
facility: Barzilai University Medical Center
Study officials:
affiliation: Barzilai University Medical Center
name: David Hauser, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06968234: Exploring Clinical Characteristics of Liver Disease Patients Based on Digestive Metabolic Exhaled Air
Official title: Exploring Clinical Characteristics of Liver Disease Patients Based on Digestive Metabolic Exhaled Air
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cirrhosis
Microbiota
Breath Tests
Lead sponsor: Shanghai Zhongshan Hospital
Sponsor class: OTHER
First posted: 2025-05-13
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with chronic liver disease and cirrhosis hospitalized at Fudan University Affiliated Zhongshan Hospital, Shanghai Institute of Geriatric Medicine, and Minhang District Central Hospital.

Brief summary: Cirrhosis is a common digestive system disease and represents the final stage of the progression of various chronic liver diseases. During cirrhosis, the intestinal microenvironment is affected due to liver damage and increased portal venous pressure. Displacement of gut microbiota is closely related to the occurrence and development of cirrhosis. Disruption of the gut microbiota is associated with changes in the levels of nitric oxide (NO), hydrogen (H₂), methane (CH₄), and hydrogen sulfide (H₂S). Breath testing is an emerging method for assessing gut microbiota. This project aims to investigate the characteristics and prognosis of patients with chronic liver disease by detecting exhaled breath markers such as nitric oxide (NO), hydrogen (H₂), methane (CH₄), and hydrogen sulfide (H₂S), in conjunction with results from serological tests, gut microbiota analysis, and radiomics. The goal is to identify new diagnostic biomarkers and therapeutic targets, to recognize high-risk patients at an early stage, and to improve patient survival rates and quality of life.


Eligibility criteria: Inclusion Criteria:

① Patients diagnosed with chronic liver disease or cirrhosis through liver biopsy pathology or clinical laboratory and imaging examinations;

② Undergo molecular breath testing within one week of admission.

Exclusion Criteria:

* Patients who have received antibiotic treatment within one month; ② Patients with severe pulmonary diseases, such as chronic obstructive pulmonary disease (COPD), asthma, or lung malignancies that have not been clinically cured; ③ Patients who are unable to successfully complete the molecular breath test.

Primary outcomes:
measure: Gastrointestinal bleeding
timeFrame: 2 months
Secondary outcomes:
measure: The occurrence of clinical events
timeFrame: 6 months, 1 year, and 2 years
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Geriatrics Medical Center
state: Shanghai
city: Shanghai
country: China
facility: Shanghai Minhang District Central Hospital
state: Shanghai
city: Shanghai
country: China
facility: Zhongshan Hospital
state: Shanghai
Study officials:
affiliation: Shanghai Zhongshan Hospital
name: Shiyao Chen, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02504034: Interventional Radiology for the Treatment of Symptomatic Portal Hypertension in Patients With Cavernous Transformation of Portal Vein
Official title: Interventional Radiology for the Treatment of Symptomatic Portal Hypertension in Patients With Cavernous Transformation of Portal Vein
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Portal Vein, Cavernous Transformation Of
Hypertension, Portal
Keywords: Portal Vein, Cavernous Transformation Of
Hypertension, Portal
Radiology, Interventional
Portalsystemic shunt
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2015-07-21
Enrollment: 150
Sex: ALL
Minimum age (years): 1
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the values of portosystemic shunt and other interventional radiology approaches for treatment of symptomatic portal hypertension in patients with cavernous transformation of portal vein.


Eligibility criteria: Inclusion Criteria:

* All patients with portal hypertention who have enough image information to confirm cavernous transformation of portal vein.

Exclusion Criteria:

* Patients with known severe dysfunction of heart, lung, brain, kidney and other vital organs.

Primary outcomes:
measure: Incidence Rate of Gastrointestinal Bleeding
timeFrame: 1 month
measure: Ascites Volume (mL)
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Department of Radiology
state: Guangdong
Study officials:
affiliation: Sun Yat-sen University
name: Zaibo Jiang, MD.
role: STUDY_CHAIR
References:
Clinical trial NCT00078234: Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia
Official title: A Pilot Study of Genasense® (G3139, Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated Subjects With Chronic Lymphocytic Leukemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Chronic Lymphocytic Leukemia
Keywords: CLL
Leukemia
Chronic
Cancer
Adult
Lymphocytic
Genasense
G3139
Genta
Bcl-2
Antisense
Oligonucleotide
oblimersen
Lead sponsor: Genta Incorporated
Sponsor class: INDUSTRY
First posted: 2004-02-23
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The treatment combination of Rituxan® (rituximab) and fludarabine has previously been reported to produce a high percentage of responses with less toxicity than other combination treatments. However, some leukemia subjects continue to have leukemia despite treatment with these standard anticancer drug therapies, or they may work for only a short period of time. In some subjects, when the leukemia does not respond well to therapy the leukemia cells may be over-producing one or more proteins. One of these proteins is called Bcl-2. Bcl-2 is a protein that appears to protect cancer cells from being killed and thus lengthens the life of the cancer cells. Genasense® (oblimersen sodium) is a compound that blocks production of the Bcl-2 protein. By first lowering levels of Bcl-2, it is possible that chemotherapy drugs may work more effectively as a cancer treatment. Genasense® may also directly kill CLL cells. This study will test whether treating subjects with Genasense®, fludarabine and rituximab is safe and effective.


Eligibility criteria: Key Inclusion Criteria:

* Absolute lymphocyte count of \> 10,000 cells/mm3 or history of ALC \>10,000 cell/mm3
* Platelets \> 50,000 cells/mm3
* Tumor lymphocytes expressing surface CD5, CD19, CD20 and CD23
* Creatinine \< 1.5 mg.dL

Key Exclusion Criteria:

* Less than 3 weeks from any prior major surgery or other therapy for CLL including radiation therapy, chemotherapy, high-dose steroid therapy, immunotherapy, cytokine, biologic or vaccine therapy.
* History of autoimmune hemolytic anemia
* Prior allogeneic transplant

Primary outcomes:
measure: Safety and complete response rate
timeFrame: Monthly for response
Secondary outcomes:
Other outcomes:
Locations:
city: Washington
country: United States
facility: Georgetown University Medical Center/Lombardi Cancer Center
state: District of Columbia
city: Buffalo
country: United States
facility: Roswell Park Cancer Institute
state: New York
city: New Hyde Park
country: United States
facility: Long Island Jewish Medical Center
state: New York
Study officials:
References:
Clinical trial NCT06485934: Kinesiophobia Scale for the Upper Extremity
Official title: Development of the Multidimensional Kinesiophobia Scale for the Upper Extremity: A Scale Development Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Shoulder Injuries
Keywords: Kinesiophobia
Shoulder
Development of Scale
Lead sponsor: Karadeniz Technical University
Sponsor class: OTHER
First posted: 2024-07-03
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Traumatological, orthopedic and rheumatological pathologies that cause fear of movement in the upper extremity

Brief summary: Questionnaires/scales used to evaluate kinesiophobia in the literature are limited and are not specific to the upper extremity in existing scales. For this reason, the primary purpose and subject of the study is to develop a multi-factor kinesiophobia scale specific to shoulder problems.

The study is an observational research. Participants will be interviewed twice in total. All primary and secondary outcomes will be assessed at the first meeting. The second come will be performed within 5-7 days after the first assessment. In the second come, only the new kinesiophobia scale that is intended to be developed will be applied.


Eligibility criteria: Inclusion Criteria:

* Tampa Kinesiophobia Score \>37 points
* Presence of traumatological, orthopedic and rheumatological pathology in the upper extremity
* Mini-Mental State Examination score \>24 points

Exclusion Criteria:

* Malignancy,
* Psychiatric drug use,
* Use of painkillers during evaluation periods,
* Those who received physiotherapy before the study (last 6 months),
* Those whose education level is below secondary school level,

Primary outcomes:
measure: Multidimensional Kinesiophobia Scale (To be developed)
timeFrame: Baseline of the study
measure: Multidimensional Kinesiophobia Scale (To be developed)
timeFrame: 5-7 days after baseline assessment
Secondary outcomes:
measure: Visual Analog Scale
timeFrame: Baseline of the study
measure: Tampa Kinesiophobia Scale
timeFrame: Baseline of the study
measure: Demographic Data Form
timeFrame: Baseline of the study
Other outcomes:
Locations:
city: İstanbul
country: Turkey
facility: Clinic of İstanbul Hand-Microsurgery Rehabilitation
city: İstanbul
country: Turkey
facility: Clinic of İstanbul Hand-Microsurgery Rehabilitation
Study officials:
affiliation: Bitlis Eren University
name: Abdurrahman Tanhan, PhD
role: STUDY_CHAIR
affiliation: Biruni University
name: Zeynep Hoşbay, Associate Professor
role: STUDY_CHAIR
References:
Clinical trial NCT02043834: Virtual Reality-based Exercise in Older Adults
Official title: Promoting Virtual Reality-based Exercise to Prevent Falls in Older Adults: Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Distorted; Balance
Motor Deficit
Lead sponsor: University of Arizona
Sponsor class: OTHER
First posted: 2014-01-23
Enrollment: 33
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the present study is to evaluate an innovative virtual reality-based balance training intervention for improving clinically relevant motor performances (balance and gait) in older adults.

We hypothesize that the virtual reality-based balance training intervention will improve balance and gait performances in older adults compared to a control group receiving usual care only.


Eligibility criteria: Inclusion Criteria:

* ability to ambulate without assistance
* willingness to provide informed consent

Exclusion Criteria:

* severe neurologic, cardiovascular, metabolic, or psychiatric disorders
* severe visual impairment
* cognitive impairment

Primary outcomes:
measure: Postural Balance
timeFrame: after 4 weeks
Secondary outcomes:
measure: Gait performance
timeFrame: 4 weeks
measure: Cognitive status
timeFrame: 4 weeks
measure: Quality of life
timeFrame: 4 weeks
measure: Functional performance
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Tucson
country: United States
facility: Villa Hermosa - Senior Living Tucson
state: Arizona
Study officials:
affiliation: interdisciplinary Consortium on Advanced Motion Performance (iCAMP), Department of Surgery, College of Medicine, University of Arizona
name: Bijan Najafi, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: interdisciplinary Consortium on Advanced Motion Performance (iCAMP), Department of Surgery, College of Medicine, University of Arizon
name: Michael Schwenk, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Schwenk M, Grewal GS, Honarvar B, Schwenk S, Mohler J, Khalsa DS, Najafi B. Interactive balance training integrating sensor-based visual feedback of movement performance: a pilot study in older adults. J Neuroeng Rehabil. 2014 Dec 13;11:164. doi: 10.1186/1743-0003-11-164.
Clinical trial NCT04015934: Predictive Factors of Long Term Outcome in MMN
Official title: Predictive Factors Identification of Long-term Outcome in Multifocal Motor Neuropathy (MMN) Treated With Intravenous Immunoglobulin (IVIG)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: MMN
Keywords: predictive factors
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
Collaborators: name: Centre Hospitalier Régional Metz-Thionville
name: Hospices Civils de Lyon
First posted: 2019-07-11
Enrollment: 54
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: MMN patients

Brief summary: The cornerstone treatment for multifocal motor neuropathy (MMN), a rare and disabling dysimmune neuropathy, is intravenous immunoglobulin (IVIg). The aim of this study is to identify prognostic factors of poor outcome.

Data were retrospectively collected from MNN patients in three French centers. Patients were divided into two groups: a good outcome group and a poor outcome group. Demographic, clinical, biological and nerve conduction study features of MMN patients were analyzed. Identification of prognostic factors in MMN could help develop personalized treatment.

Detailed description: The cornerstone treatment for multifocal motor neuropathy (MMN), a rare and disabling dysimmune neuropathy, is intravenous immunoglobulin (IVIg). However, 10% of patients progress despite treatment. The aim of this study is to identify prognostic factors of poor outcome.

Data were retrospectively collected from MNN patients in three French centers. Patients were divided into two groups: a good outcome group (patients in remission without IVIg or with spaced IVIg courses), and a poor outcome group (patients dependent on continuous IVIg treatment or deteriorating despite IVIg). Investigators searched predictive factors of long-term outcome in MMN. They studied demographic, clinical, biological and nerve conduction study features of MMN patients.Identification of prognostic factors in MMN could help develop personalized treatment by selecting patients eligible for immunosuppressive drugs before IVIg dependence or progression.

Eligibility criteria: Inclusion Criteria:

* diagnosis of MNN following the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) Guideline criteria 2010

Exclusion Criteria:

* missing data
* clinical progression features suggested another inflammatory neuropathy,
* immunosuppressive agents for another pathology.

Primary outcomes:
measure: Presence of deteriorating or strongly dependant IVIg NMM
timeFrame: inclusion
Secondary outcomes:
Other outcomes:
Locations:
city: Nancy
country: France
facility: Central Hospital
Study officials:
References: